Markets:

Overview

News

Currencies

International

Treasuries

Seagen Inc. - Common Stock (NQ:SGEN)

N/A UNCHANGED

Last Price Updated: 4:00 PM EST, Dec 13, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Seagen Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

3 Steal-of-a-Deal Stocks to Snap Up Right Now ↗

February 26, 2024

Here are three steal-of-a-deal stocks that offer meaningful upside for investors looking for stocks that are on sale now.

Via InvestorPlace

Outdoing Cancer Requires Pharma To Go Beyond Merely Revolutionizing Existing Treatment ↗

February 22, 2024

Pfizer Inc (NYSE: PFE) is among the many pharmaceutical companies that turned to oncology in response to sinking demand for its COVID-19 products and near patent expiration dates for its several...

Via Benzinga

Topics Intellectual Property

Get Rich Quick with These 7 Growth Stocks to Buy Now ↗

February 20, 2024

Here are seven growth stocks to buy that will let you know by their price action if the current bull market is ready to expand.

Via InvestorPlace

7 Dividend Stocks to Buy at a 52-Week Low ↗

February 12, 2024

Each of these dividend stocks has been down sharply in the last 12 months but has fundamental reasons that support a turnaround.

Via InvestorPlace

Pfizer’s 2024 Comeback: A Dividend Gem in the Pharma Market ↗

February 01, 2024

Pfizer is in Wall Street's doghouse, but don't despair. At its current price, value seekers ought to relish the opportunity to buy PFE stock.

Via InvestorPlace

Looking Into Seagen's Recent Short Interest ↗

December 13, 2023

Via Benzinga

What the Options Market Tells Us About Seagen ↗

December 11, 2023

Via Benzinga

$100 Invested In Seagen 20 Years Ago Would Be Worth This Much Today ↗

December 07, 2023

Via Benzinga

3 Pharma Stocks Could Be the Pills Your Portfolio Needs ↗

January 18, 2024

These large-cap pharma stocks offer growth and value with existing medicines, deep pipelines and reasonable valuations.

Via InvestorPlace

How To Earn $500 A Month From Pfizer Stock ↗

January 02, 2024

Pfizer Inc. (NYSE: PFE) shares closed almost flat on Friday, but lost around 44% during 2023.

Via Benzinga

Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024 ↗

December 29, 2023

According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023.

Via Benzinga

3 Stocks That Are About to Get Absolutely Crushed ↗

December 14, 2023

These are a few different companies that are experiencing difficult times and that are expected to keep falling.

Via InvestorPlace

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $3,600 Today ↗

November 20, 2023

Via Benzinga

Here's How Much You Would Have Made Owning Seagen Stock In The Last 15 Years ↗

November 03, 2023

Via Benzinga

Pfizer's 2030 Vision Bolstered By Seagen Deal, Analyst Cuts Price Target Amid Conservative 2024 Forecast ↗

December 14, 2023

Truist Securities analyst Robyn Karnauskas reiterated a Buy rating on Pfizer, Inc. (NYSE: PFE),

Via Benzinga

Pfizer's 2024 Outlook Disappointed Wall Street, But Where Will the Stock Be in 5 Years? ↗

December 14, 2023

Pfizer recently outlined expectations for 2024 results in light of an upcoming $43 billion acquisition of Seagen.

Via The Motley Fool

3 Sleepy Stocks Ready to Wake up in 2024 ↗

December 13, 2023

Strong projected earnings growth makes these three stocks strong candidates for exceptional growth in 2024.

Via InvestorPlace

Pfizer's Dividend Yield Is 5.7%, Plus Humana And Shake Shack On CNBC's 'Final Trades' ↗

December 13, 2023

On CNBC’s "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management named Shake Shack Inc (NYSE: SHAK)

Via Benzinga

Pfizer Stock Tumble Steepens As Seagen Guidance Update Disappoints ↗

December 13, 2023

Pfizer's updated 2024 revenue figures, including Seagen, undercut the consensus target.

Via Investor's Business Daily

Why Is US Pharma Giant Pfizer Stock Trading Lower Today? ↗

December 13, 2023

Pfizer Inc (NYSE: PFE) provided its full-year 2024 guidance, which includes the expected financial impact from the Seagen Inc (NASDAQ: SGEN) transaction.

Via Benzinga

Pfizer Clears Required Regulatory Hurdles To Complete $43B Seagen Acquisition ↗

December 12, 2023

Pfizer Inc (NYSE: PFE)

Via Benzinga

Bristol Myers Squibb Further Diversifies Oncology Portfolio With Mega $8.4B Deal ↗

December 12, 2023

SystImmune and Bristol Myers Squibb & Co (NYSE: BMY)

Via Benzinga

3 Blue-Chip Stocks Set to Make a Comeback in 2024 ↗

December 08, 2023

These are the blue-chip stocks to buy as they represent quality companies with a steady growth outlook and promising cash flow growth.

Via InvestorPlace

ImmunoGen Stock Nearly Doubled On Thursday: What Happened? ↗

November 30, 2023

Shares of ImmunoGen Inc. close to doubled this morning after AbbVie Inc. said it will buy the cancer therapies company for $10.1 billion.

Via Talk Markets

Billionaire Favorites: 3 Ultra-High Yield Stocks the Elite Love ↗

November 30, 2023

Buying stocks simple for their high dividend yields is risky but these are three stocks the elite love regardless.

Via InvestorPlace

The 7 Most Undervalued Sleeper Stocks to Buy Now: November 2023 ↗

November 19, 2023

Here are just a few of the most undervalued sleeper stocks investors may want to consider heading into the new year.

Via InvestorPlace

10 Health Care Stocks Whale Activity In Today's Session ↗

November 10, 2023

Via Benzinga

BioNTech Stock Surges On Surprise Profit, Strong Sales. But Report Has Downside. ↗

November 06, 2023

The company was expected to report a third-quarter loss and plummeting sales.

Via Investor's Business Daily

This Is The 'Only Solar Stock' Jim Cramer Is Recommending 'Because It's A Pure Play' ↗

November 06, 2023

On CNBC’s "Mad Money Lightning Round," Jim Cramer said DocuSign, Inc.

Via Benzinga

CPRI, SGEN, VMW: Why These 3 Stocks Are on the Tip of Bill Gross’ Tongue ↗

November 05, 2023

Bill Gross, the Bond King, is wading into the world of equity arbitrage with these three stocks - but are they worth the risk for investors?

Via InvestorPlace

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.